The new technology could one day serve as a platform to screen drugs for Alzheimer’s and other neurological diseases. It could also enable researchers to better see how single cells communicate in large “mini-brain” networks.
The new assay offers insights to the physiological state of individual neurons in large networks that can potentially form mini-brains. This physiological state provides details about how neurons interact together and how they respond to drugs in dysfunctional or impaired networks.
One of the team’s goals is to use the platform to replicate and modify diseased networks, such as in Alzheimer’s. They are also working to discover new drug therapies to battle neurodegenerative diseases.
Nanowire geometries are ideal for interfacing with cells and measuring intracellular potentials of neurons with minimal invasiveness. This is particularly important for interfaces with human neurons to accelerate drug screening and development.
The team developed a new hybrid integration scheme that offers, for the first time, a nanowire-on-lead approach. The approach enables independent electrical addressability, is scalable, and has superior spatial resolution in vertical nanowire arrays.
The team is from the University of California San Diego, the Sanford Burnham Prebys Medical Discovery Institute, and the Center for Integrated Nanotechnologies (CINT), a Department of Energy Office of Science user facility at Los Alamos National Laboratory and Sandia National Laboratories.
The team demonstrated the fabrication of these nanowire arrays to be scalable down to submicrometer site-to-site spacing. Further, the arrays can be combined with standard integrated circuit fabrication technologies.
The team utilized these arrays to perform electrophysiological recordings from mouse and rat primary neurons and human-induced pluripotent stem cell (hiPSC) derived neurons. The recordings revealed high signal-to-noise ratios and sensitivity to subthreshold potentials that are likely generated by quantal release of neurotransmitters.
This platform paves the way for longitudinal electrophysiological experiments on synaptic activity in hiPSC-based disease models of neuronal networks, critical for the development of drugs for neurological diseases.
Source: U.S. Department of Energy, Office of Science